STOCK TITAN
  1. Home
  2. News
  3. MACK

Merrimack Pharmaceuticals Inc - MACK STOCK NEWS

Welcome to our dedicated news page for Merrimack Pharmaceuticals (Ticker: MACK), a resource for investors and traders seeking the latest updates and insights on Merrimack Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merrimack Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merrimack Pharmaceuticals's position in the market.

News
Merrimack Receives $225 Million Milestone Payment from Ipsen
Rhea-AI Summary
Merrimack Pharmaceuticals, Inc. announces a special meeting of stockholders to approve a Plan of Dissolution after receiving a $225 million payment from Ipsen, S.A. for FDA approval of ONIVYDE. The company anticipates an initial liquidating dividend of $14.68 to $15.30 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
News
Merrimack Reports Full Year 2023 Financial Results
Rhea-AI Summary
Merrimack Pharmaceuticals, Inc. announces FDA approval for Onivyde as a first-line treatment for metastatic pancreatic ductal adenocarcinoma, triggering a $225 million payment from Ipsen. The company expects to hold a special meeting to approve a Plan of Dissolution and a liquidating dividend. Financially, Merrimack reported a net loss of $1.2 million for 2023, with $18.9 million in cash and investments as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
earnings
-
News
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Rhea-AI Summary
Merrimack Pharmaceuticals, Inc. (MACK) receives a $225 million milestone payment from Ipsen following the FDA approval of Onivyde for metastatic pancreatic cancer. The company plans a special stockholder meeting to approve a dissolution plan, aiming to issue a liquidating dividend estimated between $14.65 and $15.35 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
News
Merrimack Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) reported a net loss of $279 thousand for Q3 2023, compared to a net loss of $442 thousand in Q3 2022. General and administrative expenses were $531 thousand. As of September 30, 2023, Merrimack had $18.9 million in short term investments and cash and cash equivalents. Ipsen's Onivyde® program is under review by the FDA with a goal date of February 13, 2024. Elevation Oncology is pausing further investment in seribantumab development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
earnings
-
News
Merrimack Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced its second quarter 2023 financial results, reporting a net loss of $391 thousand. Ipsen's FDA acceptance of Onivyde as a first-line treatment for metastatic pancreatic ductal adenocarcinoma could entitle Merrimack to a $225 million milestone payment. The company had cash, cash equivalents, and short-term investments of $19.0 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
earnings
-
News
Merrimack Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
News
Merrimack Reports Full Year 2022 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
earnings
-
News
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
News
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
212.75%
Tags
none
News
Merrimack Reports Third Quarter 2022 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
earnings
Stock MACK logo
Merrimack Pharmaceuticals Inc

Nasdaq:MACK

MACK Rankings

#3703 Ranked by Market Cap
#32 Ranked by Stock Gains
N/A Ranked by Dividends

MACK Stock Data

213.33M
9.40M
1.21%
66.67%
4.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About MACK

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.